
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Mol. Biosci. , 25 June 2024
Sec. Molecular Diagnostics and Therapeutics
Volume 11 - 2024 | https://doi.org/10.3389/fmolb.2024.1444446
This article is a correction to:
Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
A Corrigendum on
Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
by Vannini A, Parenti F, Forghieri C, Barboni C, Zaghini A, Campadelli-Fiume G and Gianni T (2023). Front. Mol. Biosci. 10:1149973. doi: 10.3389/fmolb.2023.1149973
In the published article, the Reference for Lopez and Olive, 2020 was incorrectly written as “Lopez, M., and Olive, D. (2020). Antibodies having specificity to nectin-4 and uses thereof. Google Patents”. It should be “Lopez, M. (2018) Antibodies having specificity to nectin-4 and uses thereof. Google Patents.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: oncolytic virus, oncolytic herpes simplex virus, retargeting, nectin4, anti-cancer vaccine, immunotherapy, pancreas carcinoma, triple negative breast cancer
Citation: Vannini A, Parenti F, Forghieri C, Barboni C, Zaghini A, Campadelli-Fiume G and Gianni T (2024) Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers. Front. Mol. Biosci. 11:1444446. doi: 10.3389/fmolb.2024.1444446
Received: 05 June 2024; Accepted: 06 June 2024;
Published: 25 June 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Vannini, Parenti, Forghieri, Barboni, Zaghini, Campadelli-Fiume and Gianni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gabriella Campadelli-Fiume, Z2FicmllbGxhLmNhbXBhZGVsbGlAdW5pYm8uaXQ=; Tatiana Gianni, dGF0aWFuYS5naWFubmkzQHVuaWJvLml0
†These authors have contributed equally to this work and share last authorship
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.